For research use only. Not for use in humans.

Azintuxizumab (Anti-SLAMF7 / CS1)

Synonyms: ABBV-383 Cat.No.A3061 Purity:99%

Azintuxizumab (Anti-SLAMF7 / CS1/ CD319/ CRACC) is a monoclonal IgG4 bispecific antibody targeting B-cell maturation antigen (BCMA). It has the potential for the research of relapsed/refractory multiple myeloma (RRMM). MW :140.12 KD.

Quality Control

Batch: A306101 Purity: 99% Protein concentration: 9.517mg/ml Endotoxin Level: ＜1EU/mg

Cited in Nature Medicine for its top-tier quality
COA
SDS
Datasheet

Mechanism of Action

Description	Azintuxizumab (Anti-SLAMF7 / CS1/ CD319/ CRACC) is a monoclonal IgG4 bispecific antibody targeting B-cell maturation antigen (BCMA). It has the potential for the research of relapsed/refractory multiple myeloma (RRMM). MW :140.12 KD.
References	[1] https://pubmed.ncbi.nlm.nih.gov/36029527/

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	1826819-57-1
Isotype	Human IgG1
Source	CHO
Formulation	100 mM Pro-Ac, 20mM Arg, pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.